Q3 was below estimates on weaker-than-expected EBITDA margin largely due to plant start-up costs. Standalone and SMR# revenue growth was below estimates, while SMP^ and PKC growth beat estimates. Consolidated EBITDA margin was a slight miss across operations, resulting in overall EBITDA miss of ~4%.